Free Submission Public Relations &
Deutsch English

Ciclopirox (Dermatophytic Onychomycosis) - Forecast and Market Analysis to 2022

Global ciclopirox market: New market research published

Print article Print article
2014-02-12 09:41:02 - Ciclopirox (Dermatophytic Onychomycosis) - Forecast and Market Analysis to 2022 - a new market research report on

Ciclopirox (Dermatophytic Onychomycosis) - Forecast and Market Analysis to 2022 - We have released our new PharmaPoint Drug Evaluation report, "Ciclopirox (Dermatophytic Onychomycosis) - Forecast and Market Analysis to 2022". Dermatophytic onychomycosis (DO) is characterized as being a fungal infection of the nail. Infection can involve the nail unit (nail matrix, nail bed, or nail plate). DO isn´t considered life-threatening, however can cause patients to experience discomfort, pain, and may cause physical and occupational limitations. DO patients can be identified as having thick or brittle nails along with discoloration (white and opaque). Physicians currently use direct microscopy and fungal culture tests to ensure correct diagnosis and treatment are achieved. Risk factors such as advanced age, pre-existing diabetes, or immunocompromised systems



can increase the incidence of DO in patients. Current therapies consist of generics that offer substantial efficacy but sub-par safety profiles. A new wave of therapies is expected to offer topical options for patients who are unable to withstand existing generic options. These therapies are also expected to drive an increase in total drug treatment rates in the US market.

Ciclopirox is currently the only topical agent that is indicated for the treatment of onychomycosis in the US. The product was marketed as Penlac Nail Lacquer by Dermik Laboratories, a subsidiary of Aventis Pharmaceuticals, and was originally approved by the Food and Drug Administration (FDA) in 1999. Clinical studies showing the efficacy of ciclopirox have primarily demonstrated its efficacy against T. rubrum infections, which allows ciclopirox to be indicated and prescribed for dermatophyte-related onychomycosis. The actual MOA of ciclopirox has been suggested to involve the chelation of polyvalent cations, which inhibits the metal-dependent enzymes that are responsible for the dissolution of the fungal cell wall.


- Overview of Dermatophytic Onychomycosis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Ciclopirox including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Ciclopirox for the US from 2012 to 2022.
- Sales information covered for the US

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Dermatophytic Onychomycosis
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Ciclopirox performance
- Obtain sales forecast for Ciclopirox from 2012 to 2022 in the US

Click for report details: ..

Browse all Healthcare and Medical Market Research Reports ..

Browse all Healthcare and Medical Company Profile Reports ..

Browse all Latest Market Research Reports ..

About Us is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles,’s online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.

Mike King
Phone: London: +44 (0) 203 086 8600

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News


Terms & Conditions | Privacy | About us | Contact